Figure 3.
Combined administration of oleanolic acid (OA) and oleuropein (OP) prevented gains in body weight andEDF mass. (A) Experimental protocol, (B) body weight, (C) EDF mass, (D) food intake, (E) energy intake, (F) water intake, (G) mRNA expression levels of TGR5, PGC-1α, and Sirt1 in EDF, (H) mtDNA copy numbers in EDF, (I) glycerol released from adipocytes to medium by administration of OA or OA + SBI-155 (TGR5 antagonist), (J) glycerol released from adipocytes to medium by administration of OP or OP + GW9662 (PPARγ antagonist), (K) plasma glycerol concentration after oral administration of oleanolic acid, or (L) oleuropein. Data are expressed as mean ± SEM. *p < 0.05 vs. (physical inactivity) PI + high-fat diet (HFD) as determined by an unpaired, two-tailed t test.